| [1] |
Moe S, Drüeke T, Cunningham J, et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from kidney disease: improving global outcomes (KDIGO)[J]. Kidney Int, 2006, 69(11): 1945-1953.
|
| [2] |
Cunningham J, Locatelli F, Rodriguez M. Secondary hyperparathyroidism: pathogenesis, disease progression, and therapeutic options[J]. Clin J Am Soc Nephrol, 2011, 6(4): 913-921.
|
| [3] |
Ketteler M, Evenepoel P, Holden R M, et al. Chronic kidney disease-mineral and bone disorder: conclusions from a kidney disease: improving global outcomes (KDIGO) controversies conference[J]. Kidney Int, 2025, 107(3): 405-423.
|
| [4] |
王荣福, 张春丽. 核医学[M]. 4版. 北京: 北京大学医学出版社, 2019: 178-182.
|
|
Wang R F, Zhang C L. Nuclear medicine[M]. 4th ed. Beijing: Peking University Medical Press, 2019: 178-182.
|
| [5] |
陈香美. 肾脏病学[M]. 4版. 北京: 人民卫生出版社, 2020: 1425-1435.
|
|
Chen X M. Nephrology[M]. 4th ed. Beijing: People's Medical Publishing House, 2020: 1425-1435.
|
| [6] |
Block G, Hulbert-Shearon T, Levin N, et al. Association of serum phosphorus and calcium × phosphate product with mortality risk in chronic hemodialysis patients: a national study[J]. Am J Kidney Dis, 1998, 31(4): 607-617.
|
| [7] |
Wang Y J, Di Y, Li Y Q, et al. Role of sphingolipid metabolism signaling in a novel mouse model of renal osteodystrophy based on transcriptomic approach[J]. Chin Med J, 2025, 138(1): 68-78.
|
| [8] |
Kay A M, Simpson C L, Stewart J A Jr. The role of AGE/RAGE signaling in diabetes-mediated vascular calcification[J]. J Diabetes Res, 2016, 2016(1): 6809703.
|
| [9] |
Jia G H, Aroor A R, Hill M A, et al. Role of renin-angiotensin-aldosterone system activation in promoting cardiovascular fibrosis and stiffness[J]. Hypertension, 2018, 72(3): 537-548.
|
| [10] |
Stenvinkel P. Inflammation in end-stage renal disease: the hidden enemy[J]. Nephrology (Carlton), 2006, 11(1): 36-41.
|
| [11] |
Evenepoel P, Jørgensen H S, Bover J, et al. European Renal Osteodystrophy (EUROD) initiative: towards a multidisciplinary management of bone disease in chronic kidney disease[J]. Nephrol Dial Transplant, 2025, 40(1): 48-59.
|
| [12] |
Wang H, Zhang L, Chen J. Diagnostic tools for chronic kidney disease-mineral and bone disorder: a comprehensive review[J]. Metabolites, 2025, 15(4): 460.
|
| [13] |
刘志红, 李贵森. 中国慢性肾脏病矿物质和骨异常诊治指南[M]. 北京: 人民卫生出版社, 2019: 9-14.
|
|
Liu Z H, Li G S. China guidelines for diagnosis and treatment of chronic kidney disease-mineral and bone disorder[M]. Beijing: People′s Medical Publishing House, 2019: 9-14.
|
| [14] |
Xu X, Wang Y, Cheng Z, et al. The value of changes in metabolic parameters on 18F-FDG PET/CT for evaluating vascular inflammatory response in patients with diffuse large B-cell lymphoma[J]. BMC Med Imaging, 2025, 25(1): 22.
|
| [15] |
Ma X, Li D, Wang Y, et al. Association of subclinical microcalcification and inflammation with carotid plaque development: a dual-tracer PET/CT study[J]. Eur J Nucl Med Mol Imaging, 2025, 52(3): 891-902.
|
| [16] |
Singhal A, Tawakol A. PET imaging of carotid atherosclerosis: methodology, implications, and utility in cerebrovascular disease[J]. Stroke, 2025, 56(1): 211-222.
|
| [17] |
Yang Q, Wang H, Li J, et al. Advances in noninvasive diagnosis of renal osteodystrophy[J]. Ren Fail, 2025, 47(1): 41309376.
|
| [18] |
Fogelman I, Carr D. A comparison of bone scanning and radiology in the evaluation of patients with metabolic bone disease[J]. Clin Radiol, 1980, 31(3): 321-326.
|
| [19] |
Even-Sapir E. Imaging of malignant bone involvement by morphologic, scintigraphic, and hybrid modalities[J]. J Nucl Med, 2005, 46(8): 1356-1367.
|
| [20] |
El-Husseini A, Abdallah E, El-Mesery M, et al. Renal osteodystrophy in Egyptian CKD patients: observations from clinically indicated bone biopsies[J]. BMC Nephrol, 2026, 27: 147.
|